GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (FRA:S1K) » Definitions » Cyclically Adjusted Revenue per Share

Predictive Oncology (FRA:S1K) Cyclically Adjusted Revenue per Share : €0.00 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Predictive Oncology Cyclically Adjusted Revenue per Share?

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Predictive Oncology's adjusted revenue per share for the three months ended in Mar. 2024 was €0.096. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Predictive Oncology's average Cyclically Adjusted Revenue Growth Rate was -28.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -23.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -16.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Predictive Oncology was -8.30% per year. The lowest was -23.40% per year. And the median was -13.30% per year.

As of today (2024-06-17), Predictive Oncology's current stock price is €4.00. Predictive Oncology's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €0.00. Predictive Oncology's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Predictive Oncology was 0.39. The lowest was 0.01. And the median was 0.04.


Predictive Oncology Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Predictive Oncology's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Oncology Cyclically Adjusted Revenue per Share Chart

Predictive Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 484.11 360.71 409.82 338.77 -

Predictive Oncology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 230.55 200.49 289.46 - -

Competitive Comparison of Predictive Oncology's Cyclically Adjusted Revenue per Share

For the Medical Instruments & Supplies subindustry, Predictive Oncology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Predictive Oncology's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Predictive Oncology's Cyclically Adjusted PS Ratio falls into.



Predictive Oncology Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Predictive Oncology's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.096/131.7762*131.7762
=0.096

Current CPI (Mar. 2024) = 131.7762.

Predictive Oncology Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 234.000 100.560 306.641
201409 308.000 100.428 404.142
201412 135.000 99.070 179.568
201503 140.000 99.621 185.188
201506 208.000 100.684 272.233
201509 77.000 100.392 101.072
201512 168.000 99.792 221.845
201603 21.750 100.470 28.527
201606 5.846 101.688 7.576
201609 7.059 101.861 9.132
201612 5.783 101.863 7.481
201703 5.125 102.862 6.566
201706 3.065 103.349 3.908
201709 4.129 104.136 5.225
201712 5.636 104.011 7.140
201803 5.860 105.290 7.334
201806 5.203 106.317 6.449
201809 4.288 106.507 5.305
201812 3.703 105.998 4.604
201903 2.861 107.251 3.515
201906 0.843 108.070 1.028
201909 3.025 108.329 3.680
201912 1.668 108.420 2.027
202003 1.099 108.902 1.330
202006 0.331 108.767 0.401
202009 0.543 109.815 0.652
202012 0.244 109.897 0.293
202103 0.129 111.754 0.152
202106 0.113 114.631 0.130
202109 0.082 115.734 0.093
202112 0.128 117.630 0.143
202203 0.087 121.301 0.095
202206 0.098 125.017 0.103
202209 0.118 125.227 0.124
202212 0.090 125.222 0.095
202303 0.056 127.348 0.058
202306 0.113 128.729 0.116
202309 0.166 129.860 0.168
202312 0.076 129.419 0.077
202403 0.096 131.776 0.096

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Predictive Oncology  (FRA:S1K) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Predictive Oncology was 0.39. The lowest was 0.01. And the median was 0.04.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Predictive Oncology Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Predictive Oncology (FRA:S1K) Business Description

Traded in Other Exchanges
Address
2915 Commers Drive, Suite 900, Eagan, MN, USA, 55121
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.

Predictive Oncology (FRA:S1K) Headlines

No Headlines